1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Prothena Sees Potential In Targeting Amyloid, Validated By Biogen

CEO Gene Kinney Describes Company’s Emerging Alzheimer’s Programs

 
• By Mandy Jackson

Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs. 

Gene Kinney, CEO of Prothena
Prothena CEO Gene Kinney remains optimistic about targeting amyloid in Alzheimer's disease • Source: Prothena Corporation plc (Michelle Pattee)

As it nears the clinic with potential Alzheimer’s disease drugs, Prothena Corporation plc will lean on the many years of experience its leadership team has in the space, including their time at Elan Corporation working on one of the first late-stage antibodies targeting amyloid-beta. The company is working on three preclinical Alzheimer’s programs now and it sees Biogen, Inc.’s aducanumab as helping to lay the groundwork for next-generation amyloid-targeting therapies, like the one in Prothena’s pipeline.

The company is conducting preclinical studies that will enable the filing of an investigational new drug (IND) application with the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapy Areas

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.